Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia.
Bertoli, Sarah; Bérard, Emilie; Huguet, Françoise; Huynh, Anne; Tavitian, Suzanne; Vergez, François; Dobbelstein, Sophie; Dastugue, Nicole; Mansat-De Mas, Véronique; Delabesse, Eric; Duchayne, Eliane; Demur, Cécile; Sarry, Audrey; Lauwers-Cances, Valérie; Laurent, Guy; Attal, Michel; Récher, Christian.
; 121(14): 2618-26, 2013 Apr 04.
Artigo em Inglês | MEDLINE | ID: mdl-23365464
Lifting the Differentiation Embargo.
Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis.
Genomic Classification and Prognosis in Acute Myeloid Leukemia.
CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression.
How One Thing Led to Another.
[Novel therapies for acute myeloid leukemia based on genomic aberrations].
Core Circadian Clock Genes Regulate Leukemia Stem Cells in AML.
First Approved Kinase Inhibitor for AML.
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
[The diagnostic screening of acute leukemia using new technologies of automated blood analysis.]